White Paper

Biosafety Considerations For Single-Use Bioreactors

By Davy De Wilde, Joerg Weyand, Ute Husemann, Bernward Husemann, and Gerhard Greller

Sartorius_0232_PG9

Single-use bioreactors are widely accepted in the pharmaceutical industry and are increasingly being used to perform mammalian cell cultures in commercial manufacturing applications. They address some key challenges the industry faces by decreasing time-to-market, reducing validation efforts, increasing flexibility, reducing investment costs, and optimizing cost of goods.

Vaccine manufactures require a high level of flexibility from a bioreactor platform because of the large variety of cell lines they use and the number of different vaccines they produce within one facility. The flexibility offered by single-use bioreactors means that they are becoming the preferred tool for cell culture in the vaccine industry.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: